I have served as the principal investigator of the completed JUPITER trial, which was funded by AstraZeneca and evaluated the role of statin therapy among individuals with residual inflammatory risk. I have served as principal investigator of the completed CANTOS trial, which was funded by Novartis and evaluated IL-1b inhibition in cardiovascular disease. I have served as principal investigator of the completed CIRT trial, which was funded by the US National Heart Lung and Blood Institute (NHLBI) and evaluated low-dose methotrexate in cardiovascular disease. I am serving as principal investigator of studies of inflammatory biomarkers associated with eicosapent ethyl, supported by Amarin, and bempedoic acid, supported by Esperion, and am currently serving as the co-chair of the ongoing ZEUS trial, which is funded by Novo Nordisk and evaluating the role of IL-6 inhibition in cardiovascular disease. I am also a consultant for Flame, Agepha, Jannsen, and Montai Health, entities involved at least partially in the development of novel anti-inflammatory therapies that might be applied to either cardiovascular disease or cancer. I also report research grants from Kowa, Pfizer, and the NHLBI outside the area of work commented on here, and personal fees from AstraZeneca, Civi Biopharm, GSK, SOCAR, Health Outlook, New Amsterdam, Boehringer Ingelheim, Angiowave, RTI, Horizon Therapeutics, Cardio Therapeutics, the Peter Munk Advisory Bord (University of Toronto), the Leducq Foundation, Paris FR, and the Baim Institute (Boston, MA, USA), outside the area of work commented on here.